Skip Nav Destination
Issues
MYC and HSF1 Cooperate to Drive Sensitivity to Polo-like Kinase 1 Inhibitor Volasertib in High-grade Serous Ovarian Cancer
Imade Williams; Matthew O’Malley; Haddie DeHart; Bobby Walker; Vrushabh Ulhaskumar; Pranav Jothirajah; Haimanti Ray; Lisa M. Landrum; Joe R. Delaney; Kenneth P. Nephew; Richard L. Carpenter
Age at First Full-term Pregnancy and Other Reproductive Factors Are Associated with Mammographic Breast Density in Postmenopausal Women: A Study in Flanders, Belgium
Magda J. Vandeloo; Eliane Kellen; Carolyn Y. Fang; Eric A. Ross; Liesbeth Vancoillie; Liesbeth M. Bruckers; Kristof Y. Neven; Esmée M. Bijnens; Tim S. Nawrot; Chantal Van Ongeval
Stanniocalcin 1 in Patients with Refractory Colorectal Cancer Treated with Regorafenib: A Post Hoc Biomarker Analysis of the TEXCAN and CORRECT Trials
Angélique Vienot; Dewi Vernerey; Adeline Bouard; Elodie Klajer; Stefano Kim; Christophe Tournigand; Christophe Louvet; Thierry André; Benoît Rousseau; Mylène Wespiser; Laurie Spehner; Ying A. Wang; Anke Weispfenning; Emmanuelle Dochy; Christophe Borg
Expression Patterns of DLL3 across Neuroendocrine and Non-neuroendocrine Neoplasms Reveal Broad Opportunities for Therapeutic Targeting
John R. Lozada; Andrew Elliott; Mark G. Evans; James Wacker; Kathleen M. Storey; Emily A. Egusa; Nicholas A. Zorko; Akhilesh Kumar; Anthony Crymes; Elisabeth I. Heath; Benedito A. Carneiro; Heloisa P. Soares; Frank Cichocki; Jeffrey S. Miller; Emil Lou; Himisha Beltran; Emmanuel S. Antonarakis; Charles J. Ryan; Justin H. Hwang
A Phase 2 Study of Sotigalimab, a CD40 Agonist Antibody, plus Concurrent Chemoradiation as Neoadjuvant Therapy for Esophageal and Gastroesophageal Junction Cancers
Andrew H. Ko; Joseph Chao; Marcus S. Noel; Veena Shankaran; Davendra Sohal; Mary Crow; Paul E. Oberstein; Aaron J. Scott; Autumn J. McRee; Caio Max Sao Pedro Rocha Lima; Lawrence Fong; Bridget P. Keenan; Maira Soto; Erin L. Filbert; Frank J. Hsu; Xiaodong Yang
Phase Ib Study of Immunocytokine Simlukafusp Alfa (FAP-IL2v) Combined with Pembrolizumab for Treatment of Advanced and/or Metastatic Melanoma
Eva Munoz-Couselo; Ainara Soria Rivas; Shahneen Sandhu; Georgina V. Long; Miguel F. Sanmamed; Anna Spreafico; Elizabeth Buchbinder; Mario Sznol; Hans Prenen; Alexander Fedenko; Mohammed Milhem; Ana Maria Arance Fernandez; Jean-Jacques Grob; Lev Demidov; Caroline Robert; Christin Habigt; Stefan Evers; Nassim Sleiman; David Dejardin; Caroline Ardeshir; Nicole Martin; Christophe Boetsch; Jehad Charo; Volker Teichgräber; Anton Kraxner; Nino Keshelava; Oliver Bechter
Acetalax and Bisacodyl for the Treatment of Triple-Negative Breast Cancer: A Combined Molecular and Preclinical Study
William C. Reinhold; Elisabetta Marangoni; Fathi Elloumi; Remi Montagne; Sudhir Varma; Yanghsin Wang; Keyvan Rezai; Ludivine Morriset; Ahmed Dahmani; Rania El Botty; Léa Huguet; Makito Mizunuma; Naoko Takebe; Samuel Huguet; Augustin Luna; Yves Pommier
Advertisement
Email alerts
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale—within the United States—of Bavencio® (avelumab), a pharmaceutical owned by Merck. None of these funds are being, or will be, used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.
RSS Feeds